Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 23;9:5245–5255. doi: 10.2147/OTT.S110969

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Liu et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

FBXO31 reversely regulated miR-210–mediated cancer cell cycle progression and migration in breast cancer.

Notes: (A) In T47D and MCF-7 cells transfected with both C-miR210-IN and siRNAs (Si-C or Si-FBXO31), a cell cycle assay was conducted. It showed that the percentages of breast cancer cells arrested at G0/G1 phase were significantly reduced in cells transfected with Si-FBXO31, rather than in cells transfected with Si-C (*P<0.05). (B) Double-transfected T47D and MCF-7 cells were also assessed by a transwell migration assay. It was found that significantly more T47D or MCF-7 cells invaded the lower chamber while they were transfected with Si-FBXO31 than with Si-C (40×).

Abbreviations: FBXO31, F-box protein 31; miR-210, microRNA-210; Si-C, control siRNA; SiRNA, small interfering RNA; C-miR210-IN, miR-210 inhibitor.